Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s and Dementia - PowerPoint PPT Presentation

Acetylcholinesterase inhibitors in the treatment of alzheimer s and dementia
Download
1 / 20

  • 158 Views
  • Uploaded on
  • Presentation posted in: General

Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s and Dementia. Pharmaceutical Chemistry II – SSPPS 222 Based on Presentation from : Victor Ramos, Lisa Ferris, and Sarah Brown. Disease : Alzheimer’s Disease & Stats. Alzheimer’s is a form of dementia 2012 Statistics

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

Download Presentation

Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s and Dementia

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Acetylcholinesterase inhibitors in the treatment of alzheimer s and dementia

Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s and Dementia

Pharmaceutical Chemistry II – SSPPS 222

Based on Presentation from : Victor Ramos, Lisa Ferris, and Sarah Brown


Disease alzheimer s disease stats

Disease: Alzheimer’s Disease & Stats

Alzheimer’s is a form of dementia

2012 Statistics

  • 5.4 million citizens (5.2 million 65 and older)

    • One in eight older Americans

    • By 2025, 6.7 million (30% increase)

  • 2/3 of Alzheimer’s sufferers are women

  • 6th leading cause of death in the United States

  • Payments for care are estimated to exceed $200 billion

  • 80% of care is delivered by family (valued at over $210 billion)

    http://www.alz.org/downloads/facts_figures_2012.pdf


  • Disease some alzheimer s etiologies and possible t herapeutic pathways

    Disease: Some Alzheimer’s Etiologies and Possible Therapeutic pathways

    Degradation of Acetylcholine


    Disease drugs history of az drugs for different pathways

    Disease/Drugs: History of AZ Drugs for Different Pathways

    • Acetylcholinesterase inhibitors

      • 1993: Tacrine approved for mild to moderate Alzheimer’s symptoms

      • 1996: Donepezil approved for mild to severe Alzheimer’s symptoms

      • 2000: Rivastigmine approved for mild to moderate Alzheimer’s symptoms

      • 2001: Galantamineapproved for mild to moderate Alzheimer’s symptoms

    • Namenda (NMDA receptor antagonist)

      • 2003: Namenda approved for moderate to severe Alzheimer’s symptoms

      • 2010: Namenda XR approved for moderate to severe Alzheimer’s symptoms


    Target 1 ache mechanism of action

    Target 1: AChE: Mechanism of Action

    • Acetylcholinesterase breaks down Ach into choline and an acetate through hydrolysis

    • Acetylcholinesterase inhibitors block this reaction in several regions of the brain

    • There is a significant correlation between acetylcholinesterase inhibition and observed cognitive improvement


    Target acetylcholinesterase

    Target: Acetylcholinesterase

    • 2 general classes of molecular forms

      • Simple homomericoligomers of catalytic subunits

        • Founds as soluble species in cell

        • Exported

      • Heteromeric associations of catalytic subunits with structural subunits

        • Found in neuronal synapses

        • Tetramer of catalytic subunits disulfide linked to a 20kDa lipid-linked subunit

        • Outer surface of cell membrane


    Target acetylcholinesterase1

    Target: Acetylcholinesterase

    • Acetylcholinesterase rapidly hydrolyzes Ach

      • Terminates transmission at cholinergic synapses

    • Alzheimer’s may involve depletion of Ach

      • Inhibition of acetylcholinesterase could help symptoms

    • Active Site

      • Esteraticsubsite: catalytic machinery

      • Anionic subsite: binds quaternary group of Ach

      • Peripheral anionic subsite: 14Å from anionic subsite

        • Enhanced potency if drug can span both active sites


    Target acetylcholinesterase site

    Target: Acetylcholinesterase Site

    • Contains catalytic triad

      • Located at bottom of aromatic gorge

        • Deep, narrow cavity

        • 40% lined by rings of 14 aromatic amino acids

          • Primary site of interaction between quaternary group of Ach and acetylcholinesterase is aromatic ring of Trp-84

          • Trp-84 and Phe-330 part of anionic subsite

          • Trp-275 part of peripheral anionic subsite


    Drugs az ache chemical properties

    Drugs AZ-AChE: Chemical Properties


    Drug molecules

    Drug Molecules

    Tacrine

    Donepezil

    Galantamine

    • Tacrine has no chiral centers

    • Galantamine has three chiral centers and the (S,R,S) conformer is the naturally occurring form

    • Donepezil’s two stereoisomers show activity but its R-enantiomer has more activity


    Drug tacrine

    Drug: Tacrine

    • Normally, phenyl ring of Phe-330 lies parallel to surface of gorge

    • When tacrine binds, it makes contact with the bound ligand

      • Ring of Phe-330 is rotated about both X1 and X2

      • Tacrine is thus sandwiched between between the rings of Phe-330 and Trp-84

        • Recall Trp-84 is primary site of interaction between Ach and acetylcholinesterase


    Drug groups donepezil

    Drug Groups: Donepezil

    • Three segments of Donepezil, all interact with Acetylcholinesterase gorge

      • Dimethoxyindanone

        • Inandone ring has pi-pi interactions with indole ring of Trp279

      • Piperidine

        • Cation-pi interaction with Phe330

        • Ring N makes H bonds with water which makes H bonds with Tyr121

      • Benzyl

        • Parallel π–π stacking with the Trp84 indole,

        • Makes an aromatic H-bonds with water molecules that H-bond to the residues of the oxyanion hole, namely with Gly118 N, Gly119, Gly201 N, and Ser200

        • Occupies the binding site for quaternary ligands such a ACh


    Drug groups galantamine

    Drug Groups: Galantamine

    • The inhibitor spans the active site gorge, including the acyl binding site

      • Hydrogen bonding

        • Two H-bonds form between the hydroxyl of the inhibitor and Glu-199 and Ser-200 and the inhibitor’s oxygen molecule

        • Water molecules

      • Rest of interactions are Non-Polar

        • Notable that galantamine lacks the characteristic cation-pi interaction with Phe-330

        • Pi-stacking occurs between the double bonds in the cyclohexene ring of GAL and the indole ring of Trp-84

        • No charge-charge interactions


    Polar and non polar characteristics

    Polar and Non-Polar Characteristics


    Pharmacokinetic properties

    Pharmacokinetic Properties


    Drugs side effects

    Drugs: Side Effects

    • Tacrine

      • Causes elevated hepatic enzymes (CYP1A2) and is hepatotoxic

      • Tacrine metabolite is cytotoxic

      • Off market

    • Galantamine

      • Abdominal pain, diarrhea, nausea related to cholinergic effects

      • Resolve with continued treatment

    • Donepezil

      • Well tolerated at 5 mg/day

      • 13% discontinuation rate at 10 mg/day.

      • Gastrointestinal side effects are most common, related to cholinergic effects

      • All acetylcholinesterase inhibitors act through similar mechanisms, so GI side effects are similar, with severity depending on the dose administered

      • Increased acetylcholine over-stimulates cholinergic receptors in the GI tract to cause secretory and motor activity


    Drug drug interactions

    Drug-Drug Interactions

    • CYP34A inhibitors like erythromycin, cimetidine, and saquinavir increase bioavailability of the drugs and lead to increased adverse effects

    • The same is true for CYP2D6 and CYP1A2 inhibitors

    • In contrast, inducers of these metabolic enzymes like phenytoin and rifampicin will decrease bioavailability and lead to limited efficacy of the drugs


    Future treatments

    Future Treatments

    • Immunizations that utilize the immune system to attack beta-amyloid plaques

      • This went to clinical trials but was stopped when some participants developed acute brain inflammation

    • Anti-amyloid antibodies derived from other sources infused into the blood via IV

    • Preventing neurofibrillary tangles

    • Reducing chronic neuron inflammation associated with Alzheimer’s

      • NSAIDs have had variable effects


    Conclusion

    Conclusion

    • These drugs effectively inhibit acetylcholinesterase from hydrolyzing acetylcholine into choline and an acetyl group

    • However, this may or may not be effective in prolonging onset or reducing symptom severity in Alzheimer’s and does not address the underlying pathophysiology of the disease state

    • New treatments will likely target other factors involved in Alzheimer’s – drugs targeting amyloid-beta plaques and tau proteins are currently being developed

    • Combination therapies


    References

    References

    "2012 Alzheimer's Disease Facts and Figures." Alzheimer's and Dementia 8.2 (2012): 1-67. 2012. Web. 7 Mar. 2013.

    A. Koster, Hemmung der cholinesterasen in verscheidenenorganendurcheserin, galanthamine und tacrin; conzentrations-wirkungsbeziehungen, bedeuting fir die therapeutischanwendung. Dissertation 1994; MedezinsicheFakultat der Humboldt Univzu Berlin.

    Abagyan, R.,Physical Pharmacology. http://xablab.ucsd.edu/ (accessed March 5, 2013).

    "Alzheimer's Disease Treatments." Alzheimer's Disease Treatments. BrightFocus Foundation, 4 Oct. 2012. Web. 07 Mar. 2013.

    "Alzheimer's Treatments: What's on the Horizon?" Mayo Clinic. Mayo Foundation for Medical Education and Research, 06 Mar. 2013. Web. 07 Mar. 2013.

    "Drug Bank: Donepezil." DrugBank. GenomeQuest, 8 Feb. 2013. Web. 7 Mar. 2013.

    "Drug Bank: Galantamine." DrugBank. GenomeQuest, 8 Feb. 2013. Web. 7 Mar. 2013.

    "Drug Bank: Tacrine." DrugBank. GenomeQuest, 8 Feb. 2013. Web. 7 Mar. 2013.

    Greenblatt, H., et al. "Structure of AcetylcholinesteraseComplexed with (-)-galanthamine at 2.3 A Resolution." Federation of European Biochemical Societies 463 (1999): 321-26. FEBS Letters, 8 Nov. 1999. Web. 7 Mar. 2013.

    Harel, M., et al. "Quaternary Ligand Binding to Aromatic Residues in the Active-site Gorge of Acetylcholinesterase." ProcNatlAcadSci U S A 90.19 (1993): 9031-035. PubMed. Web. 7 Mar. 2013.

    Kryger, G., et al. "Structure of AcetylcholinesteraseComplexed with E2020 (Aricept®): Implications for the Design of New Anti-Alzheimer Drugs." Structure 7.3 (1999): 297-307. Elsevier Science Ltd., 1 Mar. 1999. Web. 7 Mar. 2013.

    Maccioni, R., Perry, G., Current Hypotheses and Research Milestones in Alzheimer's Disease. New York: Springer, 2009. Print.

    Massouli, J Molecular forms and anchoring of acetylcholinesterase. In, Cholinesterases and Cholinesterase Inhibitors. (Giacobini E, ed) Martin Dunitz, London, 2000 pp. 81-103

    Sussman, J.. et al. "Atomic Structure of Acetylcholinesterase from Torpedo Californica: A Prototypic Acetylcholine-Binding Protein." Science 253 (1991): 253-61. Sciencemag.org. 21 Dec. 2006. Web. 7 Mar. 2013.


  • Login